Roberta Roncarati


Area of interest:

Roberta Roncarati graduated with honors in Pharmaceutical Chemistry and Technology in 1997 at the University of Ferrara; PhD in Molecular Medicine (2009), she has been a CNR researcher since 2009. Dr. Roncarati worked from 1997 to 2004 in the United States, where she finalized her research program. She joined the laboratory of Prof. Antonio Giordano at Thomas Jefferson University, Philadelphia, for 1 year before moving to the laboratories of Prof. Carlo M. Croce at the Kimmel Cancer Institute, Philadelphia, where she studied the role of apoptotic genes (caspase-3 and Bcl2) in cardiovascular diseases in animal models, working in the team of Prof. Gianluigi Condorelli. In 1998, she started her second fellowship in the group of Prof. Luciano D’Adamio at Yeshiva University, Albert Einstein College of Medicine, Bronxn (NY), where she studied the role of Amyloid Precursor Protein in the development of Alzheimer’s disease in in vitro models. From 2000 to 2003, she carried out research and development activities at the laboratories of Aventis Pharmaceutical (Immunology Platform), Bridgwater(NJ), under the supervision of Dr Roland Kurrel. In 2004, she returned to Italy and worked at Tecnobios Prenatale Clinic, Bologna, where she carried out prenatal diagnosis research (Prof. Bovicelli). From 2006 to 2009, she worked at the ITB-CNR, Milan, focusing her interest in the identification of new mutations in familial and idiopathic cardiomyopathies using next-generation sequencing. Since 2010, she has been a researcher at the IRGB-CNR institute (UOS of Milan), where she is carrying out research in the genetics of cardiovascular diseases, using NGS approaches applied to the clinic. In 2013, she moved to the University of Ferrara (Prof. M. Negrini ), where she specialized in molecular genomics applied to cardiology and clinical oncology. She also gained experience in the study of early diagnostic markers, such as microRNAs, as regulators of gene expression in cardiovascular diseases and cancer, studying their expression profile in the plasma of affected patients. Over the last 3 years, she has focused her interest on the study of DNA methylationin liquid biopsies, using the NGS approaches, for the early diagnosis of lung cancer.

Most significant publications:


Roncarati, R; Lupini, L; Miotto, E; Saccenti, E; Mascetti, S; Morandi, L; Bassi, C; Rasio, D; Callegari, E; Conti, V; Rinaldi, R; Lanza, G; Gafà, R; Papi, A; Frassoldati, A; Sabbioni, S; Ravenna, F; Casoni, G L; Negrini, M

Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer Journal Article

In: Mol Oncol, 14 (9), pp. 2163–2175, 2020.



Roncarati, R; Anselmi, C Viviani; Losi, M A; Papa, L; Cavarretta, E; Martins, P Da Costa; Contaldi, C; Jotti, G Saccani; Franzone, A; Galastri, L; Latronico, M V; Imbriaco, M; Esposito, G; Windt, L De; Betocchi, S; Condorelli, G

Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy Journal Article

In: J Am Coll Cardiol, 63 (9), pp. 920–927, 2014.



Roncarati, R; Anselmi, C Viviani; Krawitz, P; Lattanzi, G; von Kodolitsch, Y; Perrot, A; di Pasquale, E; Papa, L; Portararo, P; Columbaro, M; Forni, A; Faggian, G; Condorelli, G; Robinson, P N

Đoubly heterozygous LMNA and ŦŦN mutations revealed by exome sequencing in a severe form of dilated cardiomyopathy Journal Article

In: Eur J Hum Genet, 21 (10), pp. 1105–1111, 2013.



Roncarati, R; Latronico, M V; Musumeci, B; Aurino, S; Torella, A; Bang, M L; Jotti, G S; Puca, A A; Volpe, M; Nigro, V; Autore, C; Condorelli, G

Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in Italian patients with hypertrophic cardiomyopathy Journal Article

In: J Cell Physiol, 226 (11), pp. 2894–2900, 2011.



Tarr, P E; Contursi, C; Roncarati, R; Noviello, C; Ghersi, E; Scheinfeld, M H; Zambrano, N; Russo, T; DÁdamio, L

Evidence for a role of the nerve growth factor receptor ŦrĄ in tyrosine phosphorylation and processing of beta-APP Journal Article

In: Biochem Biophys Res Commun, 295 (2), pp. 324–329, 2002.


Roncarati, R; Sestan, N; Scheinfeld, M H; Berechid, B E; Lopez, P A; Meucci, O; McGlade, J C; Rakic, P; DÁdamio, L

Ŧhe gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling Journal Article

In: Proc Natl Acad Sci U S A, 99 (10), pp. 7102–7107, 2002.


Scheinfeld, M H; Roncarati, R; Vito, P; Lopez, P A; Abdallah, M; DÁdamio, L

Jun NĦ2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP) Journal Article

In: J Biol Chem, 277 (5), pp. 3767–3775, 2002.



Condorelli, G; Roncarati, R; Ross, J; Pisani, A; Stassi, G; Todaro, M; Trocha, S; Drusco, A; Gu, Y; Russo, M A; Frati, G; Jones, S P; Lefer, D J; Napoli, C; Croce, C M

Ħeart-targeted overexpression of caspase3 in mice increases infarct size and depresses cardiac function Journal Article

In: Proc Natl Acad Sci U S A, 98 (17), pp. 9977–9982, 2001.


  • Via Fossato di Mortara n.70, 44121 Ferrara (Italy) c/o CUBO at Università di Ferrara, Department of Morphology , Surgery and Experimental Medicine


  • +39 0532-455870